Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.

Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ.

Urol Oncol. 2019 Nov 13. pii: S1078-1439(19)30410-7. doi: 10.1016/j.urolonc.2019.10.006. [Epub ahead of print] Review.

PMID:
31734020
2.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr.

J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7.

PMID:
31390274
3.

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME.

Clin Genitourin Cancer. 2019 Aug;17(4):241-247.e1. doi: 10.1016/j.clgc.2019.02.010. Epub 2019 Mar 19.

PMID:
31227432
4.

The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17. Review.

PMID:
31099673
5.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
6.

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.

Bergerot CD, Bergerot PG, Philip EJ, Hsu JA, Dizman N, Vaishampayan U, Dorff T, Pal SK.

J Immunother Cancer. 2019 Mar 12;7(1):71. doi: 10.1186/s40425-019-0557-5.

7.

Multiparametric liquid biopsy analysis in metastatic prostate cancer.

Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A.

JCI Insight. 2019 Mar 7;4(5). pii: 125529. doi: 10.1172/jci.insight.125529. eCollection 2019 Mar 7.

8.

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.

Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):50-60. doi: 10.1016/j.ijrobp.2018.12.047. Epub 2018 Dec 31.

PMID:
30605751
9.

Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.

Yap KK, Wong W, Ji L, Groshen S, Quinn DI, Bryce AH, Dorff TB.

Cancer Treat Res Commun. 2019;18:100114. doi: 10.1016/j.ctarc.2018.100114. Epub 2018 Nov 10.

PMID:
30529990
10.

Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.

Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S.

Urol Oncol. 2019 Jan;37(1):1-11. doi: 10.1016/j.urolonc.2018.09.008. Epub 2018 Nov 20. Review.

PMID:
30470611
11.

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.

12.

Low-dimensional dynamical characterization of human performance of cancer patients using motion data.

Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, Nieva J, Kuhn P, Newton PK.

Clin Biomech (Bristol, Avon). 2018 Jul;56:61-69. doi: 10.1016/j.clinbiomech.2018.05.007. Epub 2018 May 18.

PMID:
29803824
13.

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.

Liu M, Zhang L, Li H, Hinoue T, Zhou W, Ohtani H, El-Khoueiry A, Daniels J, O'Connell C, Dorff TB, Lu Q, Weisenberger DJ, Liang G.

Hepatology. 2018 Oct;68(4):1412-1428. doi: 10.1002/hep.30091.

14.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

15.

Paratesticular Serous Papillary Carcinoma of High Grade and Malignant Potential: A Rare Case with a Role for Adjuvant Therapy.

Lifton J, Ghodoussipour S, Xiao GQ, Dorff T, Loh-Doyle J, Boyd SD.

Cureus. 2018 Feb 13;10(2):e2188. doi: 10.7759/cureus.2188.

16.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6. Erratum in: J Clin Oncol. 2018 Jul 10;36(20):2131.

17.

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.

Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM.

BMC Cancer. 2018 Apr 3;18(1):368. doi: 10.1186/s12885-018-4306-9.

18.

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

Dorff TB, Agarwal N.

Asian J Androl. 2018 May-Jun;20(3):215-220. doi: 10.4103/aja.aja_12_18. Review.

19.

Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients.

Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30271-9. doi: 10.1016/j.clgc.2017.08.016. [Epub ahead of print]

PMID:
28958673
20.

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA.

Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22.

21.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr.

Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22.

22.

Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).

Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30200-8. doi: 10.1016/j.clgc.2017.07.003. [Epub ahead of print]

PMID:
28826933
23.

Chemotherapy for oligometastatic prostate cancer.

Dorff TB, Sweeney CJ.

Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446. Review.

PMID:
28817399
24.

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI.

Clin Adv Hematol Oncol. 2017 Jul;15(7):543-551. Review.

PMID:
28749918
25.

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI.

Clin Adv Hematol Oncol. 2017 Jun;15(6):466-477. Review.

PMID:
28749907
26.

A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.

Kiwata JL, Dorff TB, Todd Schroeder E, Salem GJ, Lane CJ, Rice JC, Gross ME, Dieli-Conwright CM.

BMJ Open. 2017 Jul 10;7(7):e016910. doi: 10.1136/bmjopen-2017-016910.

27.

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J.

Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8.

PMID:
28668277
28.

Current Management Strategy for Penile Cancer and Future Directions.

Dorff TB, Ballas LK, Schuckman AK.

Curr Oncol Rep. 2017 Aug;19(8):54. doi: 10.1007/s11912-017-0615-4. Review.

PMID:
28664471
29.

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.

Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA.

J Clin Oncol. 2017 May 20;35(15):1737-1743. doi: 10.1200/JCO.2016.72.0466. Epub 2017 Mar 27.

PMID:
28346805
30.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.

Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.

PMID:
28344102
31.

Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease.

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaai8700. doi: 10.1126/scitranslmed.aai8700.

32.

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G.

Front Pharmacol. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. eCollection 2016.

33.

Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series.

Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I.

BJU Int. 2017 Sep;120(3):401-408. doi: 10.1111/bju.13741. Epub 2017 Jan 14.

34.

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.

Yu SS, Quinn DI, Dorff TB.

Onco Targets Ther. 2016 Sep 23;9:5825-5837. eCollection 2016. Review.

35.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
36.

A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.

Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):323-332. doi: 10.1038/pcan.2016.25. Epub 2016 Jun 28. Review.

37.

Safety and feasibility of fasting in combination with platinum-based chemotherapy.

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI.

BMC Cancer. 2016 Jun 10;16:360. doi: 10.1186/s12885-016-2370-6.

38.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ.

J Clin Oncol. 2016 Jul 20;34(21):2478-83. doi: 10.1200/JCO.2016.66.7899. Epub 2016 May 16.

39.

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI.

Clin Genitourin Cancer. 2016 Oct;14(5):450-456.e1. doi: 10.1016/j.clgc.2016.01.013. Epub 2016 Feb 6.

PMID:
26935231
40.

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111-21. doi: 10.1038/pcan.2015.42. Epub 2016 Feb 2. Review.

41.

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer.

Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):84-91. doi: 10.1038/pcan.2015.56. Epub 2015 Dec 15.

PMID:
26666409
42.

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies.

In G, Dorff T.

Urol Clin North Am. 2015 Aug;42(3):347-57. doi: 10.1016/j.ucl.2015.04.009. Review.

PMID:
26216822
43.

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan.

Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD.

Cell Metab. 2015 Jul 7;22(1):86-99. doi: 10.1016/j.cmet.2015.05.012. Epub 2015 Jun 18.

44.

Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story.

Dorff TB, Hu J, Quinn DI.

Urol Oncol. 2015 Aug;33(8):341-2. doi: 10.1016/j.urolonc.2015.05.023. Epub 2015 Jun 18. No abstract available.

PMID:
26094170
45.

Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases.

Dorff TB, Pal SK.

Oncology (Williston Park). 2015 Jun;29(6):424, 426. No abstract available.

46.

Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?

Dorff TB, Gross ME.

Am Soc Clin Oncol Educ Book. 2015:e270-3. doi: 10.14694/EdBook_AM.2015.35.e270.

47.

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.

Vashistha V, Quinn DI, Dorff TB, Daneshmand S.

BMC Cancer. 2014 Dec 16;14:966. doi: 10.1186/1471-2407-14-966. Review.

48.

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1227-34. doi: 10.1007/s00280-014-2600-z. Epub 2014 Nov 6.

PMID:
25374407
49.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.

50.

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23.

Supplemental Content

Support Center